No ocular motility complications after subtenon topotecan with fibrin sealant for retinoblastoma

Canadian Journal of Ophthalmology

Volumn 48, Issue 6, 2013, Pages 524-528

  Yousef, Yacoub A ^a   Halliday, William ^a   Chan, Helen S L ^a   Héon, Elise ^a,b   Gallie, Brenda L ^a,b,c,d   Dimaras, Helen ^a,b,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN GLUE; TOPOTECAN;

ABSENCE OF SIDE EFFECTS; ARTICLE; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CONJUNCTIVA CONGESTION; CONJUNCTIVA DISEASE; CRYOTHERAPY; DRUG TREATMENT FAILURE; ENOPHTHALMOS; ENUCLEATION; EXTRAOCULAR MUSCLE; EYE MOVEMENT; EYE MOVEMENT DISORDER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFANT; PRESCHOOL CHILD; RANGE OF MOTION; RETINOBLASTOMA; STEREOTACTIC TREATMENT; TREATMENT RESPONSE;

CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; EYE ENUCLEATION; EYE MOVEMENT MEASUREMENTS; EYE MOVEMENTS; FIBRIN TISSUE ADHESIVE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS; OCULAR MOTILITY DISORDERS; POSTOPERATIVE COMPLICATIONS; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; TENON CAPSULE; TISSUE ADHESIVES; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TREATMENT FAILURE;

EID: 84896796725     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2013.05.018     Document Type: Article

References (27)

1. Parkin DM, Stiller CA, Draper G.J., Bieber CA The international incidence of childhood cancer. Int J Cancer. 1988;42:511-20. (Pubitemid 18264060)
2. Abramson DH. Periocular chemotherapy for retinoblastoma: success with problems? Arch Ophthalmol. 2005;123:128-9; author reply 9. (Pubitemid 40105452)
3. Abramson DH, Frank CM, Dunkel IJ A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106:1947-50.
4. Hayden BC, Jockovich ME, Murray T.G., et al Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma Invest Ophthalmol Vis Sci. 2004;45:3644-9. (Pubitemid 39298582)
5. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 2006;58:1164-81.
6. Mulvihill A, Budning A, Jay V., et al Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Oph-thalmol. 2003;121:1120-4. (Pubitemid 36962165)
7. Schmack I, Hubbard GB, Kang S.J., et al Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol. 2006;142:310-5.
8. Laurie NA, Gray JK, Zhang J, et al Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res. 2005;11:7569-78. (Pubitemid 41507720)
9. Mallipatna AC, Dimaras H, Chan H.S., et al Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol. 2011;129:738-45.
10. Tsui JY, Dalgard C, Van Quill KR, et al Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblas-toma. Invest Ophthalmol Vis Sci. 2008;49:490-6.
11. Park JR, Scott JR, Stewart C.F., et al Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011;29:4351-7.
12. Meazza C, Casanova M, Zaffignani E., et al Efficacy of top-otecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Med Oncol. 2009;26: 67-72.
13. Dimaras H, Heon E, Budning A., et al Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation. Ophthalmic Genet. 2009;30:121-6.
14. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18:41-53; viii.
15. Finger P, Harbour JW, Murphree A.L., et al Retinoblastoma. In: Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual, Chapter 52, 7th ed. New York, NY: Springer; 2009; pp. 561-568.
16. Wilson TW, Chan HS, Moselhy G.M., et al Penetration of chemotherapy into vitreous is increased by cryotherapy and cyclosporine in rabbits. Arch Ophthalmol. 1996;114:1390-5. (Pubitemid 26398725)
17. Gilbert JA, Simpson AE, Rudnick D.E., et al Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. J Control Release. 2003;89:409-17. (Pubitemid 36555900)
18. Hayden BH, Murray TG, Scott I.U., et al Subconjunctival carbo-platin in retinoblastoma: impact of tumor burden and dose schedule. Arch Ophthalmol. 2000;118:1549-54.
19. Kiratli H, Kocabeyoglu S, Bilgic S. Severe pseudo-preseptal cellulitis following sub-Tenon's carboplatin injection for intraocular retino-blastoma. J AAPOS. 2007;11:404-5. (Pubitemid 47198495)
20. Pardue MT, Hejny C, Gilbert J.A., et al Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina. 2004;24:776-82. (Pubitemid 39391771)
21. Suarez F, Jockovich ME, Hernandez E, et al Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma. Invest Ophthalmol Vis Sci. 2007;48:3437-40. (Pubitemid 351261076)
22. Mao Y, Zhongyao W, Huasheng Y., et al The experiment research of subconjunctival injections with etoposide for the treatment of retinoblastoma mice. Yan Ke Xue Bao. 2005;21: 169-174.
23. Chantada GL, Fandino AC, Carcaboso A.M., et al A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50:1492-6.
24. Marr BP, Dunkel IJ, Linker A, Abramson DH Periocular carbo-platin for retinoblastoma: long-term report (12 years) on efficacy and toxicity. Br J Ophthalmol. 2012;96:881-3.
25. Murray TG, Cicciarelli N, O'Brien JM, et al Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch Ophthalmol. 1997;115:1286-90. (Pubitemid 27435567)
26. Steinle JJ, Zhang Q, Thompson K.E., et al Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis. Invest Ophthalmol Vis Sci. 2012;53: 2439-2445.
27. L'Esperance S., Bachvarova M, Tetu B., et al Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics. 2008;9:99.